Form 4: Revolution Medicines EVP Sells Shares for Tax Obligation

Revolution Medicines' EVP of Clinical Development, Xiaolin Wang, sold 2,010 shares of common stock for $99.4804 each to cover tax withholding from RSU vesting.

Summary

• Xiaolin Wang, Executive Vice President of Clinical Development at Revolution Medicines, Inc. (RVMD), reported a sale of common stock.
• The transaction involved the disposition of 2,010 shares of common stock on March 17, 2026.
• The shares were sold at a price of $99.4804 per share.
• This sale was executed under a Rule 10b5-1 instruction letter adopted on November 17, 2025.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) after December 15, 2025.
• Following this transaction, Wang beneficially owns 116,063 shares, which includes 48,700 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned under a 10b5-1 plan specifically to cover tax obligations from RSU vesting, which is a routine occurrence.

Positives

• The sale was pre-planned under a Rule 10b5-1 plan, indicating it was not a discretionary sale based on new, non-public information.
• The sale was specifically to cover tax withholding obligations upon RSU vesting, which is a common and expected event for executives receiving equity compensation.

Negatives

• An insider sale, even for tax purposes, reduces the insider's direct equity stake in the company.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider sales for tax withholding are a routine part of executive compensation and do not typically signal a change in management's outlook on the company's prospects. This is a standard practice for executives receiving equity compensation across various industries.

Stakeholder Impact

• Shareholders: Minor dilution from the sale, but the pre-planned nature for tax purposes mitigates negative sentiment regarding insider confidence.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider sale for tax withholding purposes, which is a common event for executives receiving equity compensation. It does not indicate a change in the company's fundamentals or the insider's long-term view, thus a 'hold' recommendation is appropriate as this specific filing provides no new information to alter an existing investment thesis.

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Sale, Executive Compensation, RSU, Tax Withholding, Xiaolin Wang, Clinical Development